Application Number Funding Recommendation Title Score TR1-01249 Recommended---- Enhancing healing via Wnt-protein mediated activation of endogenous stem cells 94 TR1-01246 Recommended---- Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery 87 TR1-01257 Recommended---- Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders 85 TR1-01215 Recommended---- Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product 85 TR1-01273 Recommended---- Curing Hematological Diseases 85 TR1-01272 Recommended---- Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration 84 TR1-01245 Recommended---- Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease 84 TR1-01216 Recommended---- Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis 84 TR1-01276 Recommended---- Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines 81 TR1-01219 Recommended---- Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration 81 TR1-01227 Recommended---- Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation 79 TR1-01267 Recommended---- Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) 79 TR1-01250 Recommended---- Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation 78 TR1-01277 Recommended---- Developing induced pluripotent stem cells into human therapeutics and disease models 77 TR1-01269 Recommended---- In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies 77 TR1-01274 Not recommended---- Multipotent stem cells and renal progenitors derived from amniotic fluid as potential tools for chronic kidney disease therapies 72 TR1-01212 Not recommended---- Development of a device for the identification and quantification of cancer stem cells 71 TR1-01236 Not recommended---- Targeting Cancer Stem Cells Via Small Molecule CBP/β-Catenin Antagonists 70 TR1-01229 Not recommended---- Treatment of Sickle Cell Anemia and Thalassemia 70 TR1-01214 Not recommended---- Pluripotent stem cells for regenerating and regulating immunity 70 TR1-01265 Not recommended---- Depletion of Teratoma-Forming Cells for hESC-Based Transplantation Technologies 69 TR1-01200 Not recommended---- Development of Cell Therapy for Epilepsy 69 TR1-01204 Not recommended---- Overcoming the Translational Challenges of Using Pluripotent Stem Cells for Therapy in an Ischemic Cardiomyopathy Model 69 TR1-01226 Not recommended---- Adult Stem Cells from Human Uterus and Novel Biomaterials for Pelvic Floor Regeneration 68 TR1-01228 Not recommended---- Identification of cancer stem cell-specific internalizing scFvs for pre-clinical antibody-drug conjugate development 67 TR1-01266 Not recommended---- Stem Cell Transplantation for Pediatric Neurodegenerative Disease 66 TR1-01232 Recommended if funds allow---- Mouse Models for Stem Cell Therapeutic Development 66 TR1-01255 Not recommended---- Screening and Development of Novel Therapeutics for Sickle Cell Disease and Thalassemia 65 TR1-01211 Not recommended---- Building complex tissues: Converting Dissociated Stem Cells into Hair Organs for Burn Patients 65 TR1-01271 Not recommended---- Identification of an ES cell-based development candidate for Huntington's disease 65 TR1-01258 Not recommended---- Hepatic progenitors from human pluripotent stem cells for research and therapy 62 TR1-01263 Not recommended---- A Double Edged Sword - Cell Death & Proliferation: A Major Bottleneck for Stem Cell-Based Applications 61 TR1-01223 Not recommended---- Novel Small Molecules for Stem Cell-based Therapies 61 TR1-01205 Not recommended---- Towards hES cell therapy for Type 1 diabetes -- TR1-01242 Not recommended---- Overcoming Bottlenecks to Cardiac Regenerative Therapy -- TR1-01268 Not recommended---- Adult human pancreatic endocrine stem cells: Induction of beta-cell differentiation through chemical genomics and transplantation of encapsulated cells as an integrated approach to the treatment of type I diabetes -- TR1-01206 Not recommended---- Bone Marrow-Derived SB618 Cells for Re-myelination Therapy -- TR1-01218 Not recommended---- Reprogramming of Adult Cells into Transplantable Stem Cells -- TR1-01209 Not recommended---- Development of Therapeutic Monoclonal Antibodies to Myeloid Leukemia Cancer Stem Cells -- TR1-01252 Not recommended---- Isolation, purification, cryopreservation, expansion, differentiation and characterization of homogeneous populations of cells derived from the placenta and amnion for therapeutic use. -- TR1-01244 Not recommended---- Human Embryonic Stem Cell Therapy for Type I Diabetes -- TR1-01262 Not recommended---- Dual stem cell transplantation in tissue engineered scaffolds for the repair of spinal cord injury -- TR1-01234 Not recommended---- Development and Clinical Implementation of Ultra-high Speed Cell Sorting for Regenerative Medicine Applications -- TR1-01239 Not recommended---- Human Cardiac Progenitors for Autologous Cell –Based Therapy -- TR1-01275 Not recommended---- Towards a patient-specific, pluripotent cell-based therapy for Parkinson's disease -- TR1-01230 Not recommended---- Prevention and Treatment of Teratoma Formation During Stem Cell Therapy -- TR1-01261 Not recommended---- Development of nanoscale genomic methods for tracking of stem cell transplants. -- TR1-01208 Not recommended---- Microfluidics-based protocol for differentiation of human ESCs to hepatic cells -- TR1-01240 Not recommended---- Generation of patient-specific cells -- TR1-01253 Not recommended---- Generation and comprehensive characterization of induced pluripotent stem cells from somatic adult cells, without the use of viral vectors. -- TR1-01221 Not recommended---- Novel Strategy to Enhance T cell Reconstitution Post Stem Cell Transplantation -- TR1-01207 Not recommended---- Enhanced ESC-derived DA Neuronal Cells for Treating Parkinson’s Disease -- TR1-01202 Not recommended---- Model development using malignant pleural effusions for extracting and validating lung cancer stem cells. -- TR1-01278 Not recommended---- Pluripotent Cell Transplantation Induced Teratoma Prevention -- TR1-01251 Not recommended---- A universal ex vivo/in vivo hybrid platform for the in situ tracking of behavior and fate determination of defined stem cell populations: A bridge towards clinical application of stem cell therapy for CNS pathology -- TR1-01248 Not recommended---- Stem Cells and Biomimetic Nano-Matrix for Vascular Regeneration -- TR1-01203 Not recommended---- Characterization of Cancer Stem Cells in Multiple Myeloma -- TR1-01201 Not recommended---- Accelerated Repair of Vascular Injury in Diabetic Retinopathy by Autologous TGF-β-Modified Hematopoietic Stem Cells -- TR1-01254 Not recommended---- Thymic Regeneration as a Strategy to Induce Immunological Tolerance to ESC-Derived Therapies -- TR1-01217 Not recommended---- Developmental candidate: hESC derived therapies for neonatal urea cycle defects -- TR1-01270 Not recommended---- Stem cell differentiation therapy for melanoma using human experienced drugs -- TR1-01279 Not recommended---- Repairing Corneal Epithelium Using MicroRNA-Induced Embryonic-Like Stem Cells -- TR1-01243 Not recommended---- Optimizing Sorting Flow Cytometry for Translational Stem Cell Therapies -- TR1-01241 Not recommended---- Generation and Validation of Clinical Grade Stem Cell Lines for Human Trials in California. -- TR1-01237 Not recommended---- Comparative Studies of Subcutaneous, Omental, and Portal Islet Transplantation Sites -- TR1-01213 Not recommended---- PRODUCTION OF DOPAMINERGIC NEURONS FOR CELL THERAPY IN PARKINSON’S DISEASE -- TR1-01231 Not recommended---- Selection, maturation induction and enrichment of pacemaker cells from stem cells for generating biological pacemakers in clinical therapy -- TR1-01222 Not recommended---- Development of a Myocardial Repair Patch (MRP) -- TR1-01233 Not recommended---- Universal MSCs for the prevention of type I diabetes progression --